Repurposing low dose RGD-mimetics for improved heart failure treatment
Heart failure happens when the heart is not pumping blood around your body as effectively as it should. This debilitating condition can make people feel tired, breathless and develop swollen limbs. Whilst treatments are available to help reduce these symptoms, the development of new, more effective treatments could help to improve the lives of the people living with heart failure. Previous studies have suggested a low dose of drug originally developed as a cancer treatment, called cilengitide, could be effective at tackling the effects of this condition. In this project Professor Hodivala-Dilke and her team at Queen Mary, University of London will study whether this drug can help stimulate the growth of new blood vessels in injured mouse hearts, with the hope that this can help prevent other changes in the heart’s structure and function linked to heart failure. Over half a million people in the UK have been diagnosed with heart failure. If this research shows an existing medicine holds promise for this condition, it could then be tested in a clinical trial to find out if it could help to reduce symptoms for these people.
Project details
| Grant amount | £246,859 |
|---|---|
| Grant type | Project Grants |
| Application type | Project Grant |
| Start Date | 01 August 2019 |
| Duration | 3 years |
| Reference | PG/18/75/34096 |
| Status | In Progress |
